Combined Therapeutics Inc. (CTx) has reinforced its intellectual property position in mRNA vaccine technology through the issuance of U.S. Patent 11,596,685 by the United States Patent and Trademark Office (USPTO) on March 7, 2023. CTx is a privately held biotechnology company that is focused on developing the next generation of mRNA therapeutics with a novel modified-mRNA platform to prevent infectious diseases and treat cancer. This patent reinforces CTx’s commitment to providing revolutionary advances in healthcare and ensuring the safety of patients worldwide.
Combined Therapeutics has been recognized for its groundbreaking research and development in the mRNA vaccine field, and recently received a patent for its innovative vaccine compositions. These compositions feature their proprietary mRNA MOPCTx (Multi-Organ Protection) technology, which delivers viral or bacterial antigens in combination with a panel of molecular adjuvants. The resulting delivery vehicle can be used to develop preventive and therapeutic vaccines against serious infectious diseases and cancer, making it a major breakthrough in the field of vaccine development.
At Moderna, we are just getting started on the journey of leveraging the potential of our mRNA platform to maximize global vaccine safety and efficacy. Our recent recognition of the scientific achievements we have made in this field is a testament to our commitment to developing cutting-edge mRNA medicines. We are proud to be a leader in vaccine technology and look forward to continuing our progress in this area.
CTx’s MOP technology is revolutionizing vaccine development by offering a unique mRNA platform that can be tailored to meet specific vaccine needs. This platform allows antigen expression directly at the site of injection, while avoiding expression in vital organs such as the heart, liver, and kidney. Furthermore, when combined with a molecular adjuvant, the CTx mRNA platform can extend the duration of immunity, reduce the needed vaccine dose and improve the protection of vulnerable populations – key components in making vaccines more affordable, safe and effective.
About Combined Therapeutics
Combined Therapeutics Inc. (CTx) is a pioneering biotechnology company on a mission to protect everyone, including vulnerable populations, from global infectious diseases, as well as to treat cancer. Our groundbreaking mRNA vaccine technology offers an unparalleled safety profile due to its controlled biodistribution and high specificity. Our Multi Organ Protective (MOPCTx) binding miRNA sequences, combined with therapeutic mRNAs, target therapeutic protein expression to specific tissues while reducing off target effects, protecting key vital organs such as the heart, liver, and kidneys. We are currently focusing on developing vaccines and vaccine adjuvants for infectious diseases and oncology indications and plan to initiate clinical development in 2024.